YY1 and non-Hodgkin lymphoma: Considering the results in the present study and previous studies, in which knockdown of YY1 by siRNA sensitizes PC-3 cell to tumor necrosis factor-related apoptosis-inducing ligand (TRAIL)-mediated apoptosis36–39, and inhibition of YY1 expression plays an important role in rituximab or galiximab to sensitize B-NHL cell lines to Fas-induced apoptosis or TRAIL-induced apoptosis, respectively37,39, it appeared that YY1 was broadly involved in resistance of chemotherapy by cisplatin or other agents.